Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BIBB 1464 MS in Healthy Males
NCT02229838Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 1999
- Primary completion
- Sep 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BIBB 1464 in hypercholesterolemia (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum drug plasma concentration up to 38 hours, Time to reach maximum concentration up to 38 hours and 12 more. Started Jul 1999; status: completed.
02
Drugs
BIBB 1464
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02229838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229838.